Triple negative breast cancer (TNBC), lacking estrogen, progesterone and HER2 receptors, is usually more aggressive, harder to treat, associated with chemoresistance, high recurrence rates, distant metastases, and poor overall survival (OS) compared to cancers that are hormone receptor and/or HER2 positive.20, 21, 22, 23, 24, 25, 26. Here, ERBB2 is linked to cancer.